Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study | Zendy

G Shivaprakash | Zendy; KarthikS Udupa | Zendy; V Sarayu | Zendy; Joseph Thomas | Zendy; Vishal Gupta | Zendy; LC Pallavi | Zendy; Sudhakar Pemminati | Zendy

Open Access

Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study

Author(s) -

G Shivaprakash,

KarthikS Udupa,

V Sarayu,

Joseph Thomas,

Vishal Gupta,

LC Pallavi,

Sudhakar Pemminati

Publication year - 2017

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/ijp.ijp_846_16

Subject(s) - nausea , aprepitant , vomiting , medicine , cyclophosphamide , regimen , breast cancer , olanzapine , mucositis , anthracycline , chemotherapy , gastroenterology , antiemetic , cancer , anesthesia , schizophrenia (object oriented programming) , psychiatry

Despite the guideline-directed therapy, complete absence of nausea was noted only in 33% of breast cancer patients on anthracycline-cyclophosphamide regimen. Hence, we sought to compare the efficacy of aprepitant (APT) versus olanzapine (OLP) in preventing chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients on doxorubicin-cyclophosphamide regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research